CN112618590A - Xuesaitong dispersible tablet and preparation method thereof - Google Patents
Xuesaitong dispersible tablet and preparation method thereof Download PDFInfo
- Publication number
- CN112618590A CN112618590A CN202110084700.3A CN202110084700A CN112618590A CN 112618590 A CN112618590 A CN 112618590A CN 202110084700 A CN202110084700 A CN 202110084700A CN 112618590 A CN112618590 A CN 112618590A
- Authority
- CN
- China
- Prior art keywords
- parts
- dispersible tablet
- xuesaitong dispersible
- xuesaitong
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Xuesaitong dispersible tablet and a preparation method thereof, the Xuesaitong dispersible tablet is prepared by micronizing a panax notoginseng saponins raw material, adding water and calcium hydrophosphate, adding acid, stirring until no precipitate exists, then adding a soda solution to adjust the pH value to 7, precipitating the precipitate, stirring and drying the precipitate and a liquid phase together to obtain a dry material, micronizing the dry material again, adding a disintegrating agent, uniformly mixing, preparing a soft material by using an adhesive, preparing wet granules by using the soft material, drying, adding an additional disintegrating agent, a flow aid and a lubricant, mixing, granulating and tabletting. The Xuesaitong dispersible tablet provided by the invention can be rapidly disintegrated in a liquid environment with pH of less than 5.5 and 36-38 ℃ within 60 seconds, the dissolution rate of 120 seconds is more than 99%, and meanwhile, the raw material of the panax notoginseng saponins has small micronized particle size and high bioavailability.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a Xuesaitong dispersible tablet and a preparation method thereof.
Background
In recent years, a plurality of pharmacologists have conducted extensive research on the pharmacological action of the panax notoginseng saponins, and the research shows that the panax notoginseng saponins have significant effects on the aspects of protecting ischemic brain injury, protecting ischemic myocardial injury, improving arrhythmia, resisting platelet aggregation, resisting thrombosis, resisting liver fibrosis, protecting liver ischemic injury, improving immune function and the like, and detailed and deep research on the action mechanism of the panax notoginseng saponins shows that the panax notoginseng saponins belong to nonspecific calcium pump agonists, and the research also proves that the panax notoginseng saponins can correct the pathological state of myocardial energy imbalance, and can also obviously improve the activity of a calcium pump on a plasma reticulum in a myocardial cell while reducing blood pressure and improving the diastolic function of a left ventricle. In the department of traditional Chinese medicine of Yunnan province, 26 cases of senile cardiovascular and cerebrovascular diseases are treated by using the panax notoginseng saponins dissolved medicine in 3 to 6 months in 1993, and the more satisfactory curative effect is achieved. Among them, 9 patients with cerebral arteriosclerosis (including two cases of cerebral thrombosis) had 8 cases of cerebral blood flow pattern recovery after treatment.
The cunshufen and the like in the national hospital of Yunnan province are used for treating 50 patients with symptoms of rotary vertigo, headache, numbness and hemiplegia of limbs, difficulty in speaking, chest pain and the like of the vertigo, the apoplexy and the hemiplegia and the chest pain of the traditional Chinese medicine patients between 10 months and 2 months of 1995, and the clinical symptoms are improved. Among them, 20 vertigo patients treated 11 cases (mainly with insufficient blood supply) with abnormality through skull Doppler examination, and 5 cases were reviewed after treatment with improvement of different degrees; in 10 patients with thoracic obstruction, 6 patients with abnormal electrocardiographic examination (myocardial ischemia, T-wave change, etc.) were treated with the above-mentioned treatment, and 4 patients were improved to different degrees. The conclusion is that the effective rate reaches 75 to 80 percent, and no adverse reaction is found in the treatment process.
Because the Xuesaitong tablets and capsules are both traditional dosage forms, the medicine has the defects of slow dissolution and incomplete absorption in the aspect of taking. Thus, more desirable dispersible tablets for thromboembolic disorders have emerged through development such as:
chinese patent with publication No. CN1164264C discloses a dispersible tablet of total saponins of panax notoginseng and its preparation method, which comprises sieving raw materials and adjuvants with 100 mesh sieve respectively, weighing total saponins of panax notoginseng, lactose, mannitol and cross-linked PVP according to prescription amount, and mixing well; making soft material with 90% ethanol as wetting agent, granulating with 18-24 mesh sieve, and drying at 50-80 deg.C. And (4) granulating by using a sieve with 18-24 meshes, adding magnesium stearate, uniformly mixing, and tabletting to obtain a finished product.
The Chinese patent with the application number of CN202010563228. X discloses a Xuesaitong dispersible tablet and a preparation method thereof, wherein the preparation method comprises the steps of respectively weighing microcrystalline cellulose, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, magnesium stearate and silicon dioxide, and then mixing the microcrystalline cellulose, the crospovidone, the croscarmellose sodium, the low-substituted hydroxypropyl cellulose, the magnesium stearate and the silicon dioxide to obtain a mixture; and tabletting the mixture by a tabletting machine to obtain the Xuesaitong dispersible tablet.
The Chinese patent with the publication number of CN1323667C discloses a notoginseng dispersible tablet, which is prepared by internally adding and externally adding a disintegrating agent through a secondary granulation method, and has better disintegration effect and dissolution.
The invention discloses a Xuesaitong dispersible tablet and a preparation method thereof, wherein the preparation method comprises the steps of uniformly mixing panax notoginseng saponins, microcrystalline cellulose PH101 and crospovidone for adding internally, preparing a soft material by using 50% ethanol, granulating by using a 16-mesh sieve, drying at 80 ℃, granulating by using the 16-mesh sieve, adding the crospovidone for adding externally and superfine silica gel powder uniformly, and tabletting to obtain the Xuesaitong dispersible tablet.
In summary, the currently available dispersible tablets or dispersible tablets of panax notoginseng are prepared by taking panax notoginseng saponins in panax notoginseng as a raw material and adding disintegrating agents, fillers, glidants, lubricants and the like, but the dispersible tablets prepared by the method have the following problems:
1. the dissolution rate of the panax notoginseng saponins is influenced by the micronization degree of the panax notoginseng saponins, namely the smaller the micronized particle size, the higher the dissolution rate of the panax notoginseng saponins, but when the particle size is smaller than a certain value, along with the increase of the specific surface area, the free energy is automatically reduced after reaching a certain degree, small particles are easy to aggregate and influence the dissolution of the medicine, and the larger particles influence the bioavailability.
2. The preparation principle is the same, the disintegrating agent is expanded by water after the external addition and the internal addition of the disintegrating agent for disintegration, and the Chinese pharmacopoeia requires that the disintegrating agent is disintegrated within 3 minutes, so the disintegrating time of the Xuesaitong dispersible tablet in the prior art is longer.
Disclosure of Invention
The invention aims to provide a Xuesaitong dispersible tablet which can be rapidly disintegrated in an acidic environment, has high dissolution rate and high bioavailability, and a preparation method thereof.
In order to achieve the purpose, the invention provides a Xuesaitong dispersible tablet which is composed of panax notoginseng saponins, calcium hydrophosphate, a filler, a disintegrant, a glidant, a lubricant and an adhesive, and the Xuesaitong dispersible tablet disintegrates within 60 seconds in a liquid environment with the pH of less than 5.5 and 36-38 ℃, and the 120-second dissolution rate is more than 99%.
Wherein the filler is microcrystalline cellulose;
the disintegrating agent is carboxymethyl starch and cross-linked polyvinylpyrrolidone;
the glidant is magnesium stearate;
the lubricant is micro silica gel powder;
the binder was 95% ethanol.
Wherein, the components comprise 20 weight parts of panax notoginseng saponins, 90 to 110 weight parts of calcium hydrophosphate, 60 to 80 weight parts of microcrystalline cellulose, 20 to 30 weight parts of carboxymethyl starch, 10 to 30 weight parts of cross-linked polyvinylpyrrolidone, 1 to 10 weight parts of magnesium stearate, 1 to 5 weight parts of superfine silica gel powder and 20 to 30 weight parts of 95 percent ethanol.
The invention also provides a preparation method of the Xuesaitong dispersible tablet, which comprises the following steps:
s1 micronizing the Panax notoginsenosides;
s2 adding micronized total saponins of Notoginseng radix into water, adding calcium hydrogen phosphate, homogenizing in a homogenizer, and adding hydrochloric acid to maintain pH6-6.5 during homogenizing until no precipitate exists;
s3 adding sodium carbonate solution into the liquid phase of S2 while stirring until the pH is 7, and simultaneously separating out a precipitate;
s4, stirring and drying the precipitate and the liquid phase in the S3 at the temperature of not higher than 70 ℃ until the water content is less than 10 percent to obtain a dry material;
s5, micronizing the dry material, adding carboxymethyl starch, and uniformly mixing;
s6, adding 95% ethanol to prepare soft materials, granulating, and drying the wet granules at a temperature higher than 75 ℃;
s7 granulating, adding magnesium stearate, silica gel micropowder, and crosslinked polyvinylpyrrolidone, mixing, and tabletting to obtain XUESAITONG dispersible tablet.
Wherein the micronized particle size in the step S1 is 20-30 nanometers.
Wherein the micronized particle size in the step S5 is 40-60 nm.
The Xuesaitong dispersible tablet provided by the invention has the beneficial effects that:
1. the composition can be disintegrated within 60 seconds in a liquid environment with the pH value of less than 5.5 and 36-38 ℃, and the dissolution rate of 120 seconds is more than 99%.
2. The micronized particle size of the panax notoginseng saponins is small, and the bioavailability is high.
Drawings
The present invention will be described in further detail with reference to the accompanying drawings and specific embodiments.
FIG. 1 is a block diagram of the process flow of the Xuesaitong dispersible tablet of the present invention.
Detailed Description
The technical solution in the embodiments of the present invention is clearly and completely described below with reference to the drawings in the embodiments of the present invention. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described and will be readily apparent to those of ordinary skill in the art without departing from the spirit of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
The invention provides a Xuesaitong dispersible tablet, which consists of panax notoginseng saponins, calcium hydrophosphate, a filler, a disintegrant, a glidant, a lubricant and an adhesive, and is disintegrated in a liquid environment with the pH of less than 5.5 and 36-38 ℃ within 60 seconds, and the dissolution rate of 120 seconds is more than 99 percent.
The filler is microcrystalline cellulose; the disintegrating agent is carboxymethyl starch and cross-linked polyvinylpyrrolidone; the glidant is magnesium stearate; the lubricant is micro silica gel powder; the binder was 95% ethanol.
The composition is prepared into one thousand-tablet dispersible tablets by 20g of panax notoginseng saponins, 90-110g of calcium hydrophosphate, 60-80g of microcrystalline cellulose, 20-30g of carboxymethyl starch, 10-30g of cross-linked polyvinylpyrrolidone, 1-10g of magnesium stearate, 1-5g of superfine silica gel powder and 20-30g of 95% ethanol.
The preparation method of the Xuesaitong dispersible tablet comprises the following steps:
s1 micronizing the Panax notoginsenosides to particle size of 20-30 nm;
s2 adding micronized total saponins of Notoginseng radix into 2000ml water, adding calcium hydrogen phosphate, homogenizing, and adding 0.5mol/L hydrochloric acid to maintain pH6-6.5 during homogenizing process until no precipitate exists;
s3 adding sodium carbonate solution into the liquid phase of S2 while stirring until the pH is 7, and simultaneously separating out a precipitate;
s4, stirring and drying the precipitate and the liquid phase in the S3 at the temperature of not higher than 70 ℃ until the water content is less than 10 percent to obtain a dry material;
s5, micronizing the dry material, adding carboxymethyl starch according to the prescription amount, and uniformly mixing, wherein the particle size of the micronized powder is 40-60 nanometers;
s6, adding 95% ethanol according to the prescription amount to prepare soft materials, granulating, and drying the wet granules at a temperature higher than 75 ℃;
s7 granulating, adding magnesium stearate, silica gel micropowder, and crospolyvinylpyrrolidone, mixing, and tabletting to obtain XUESAITONG dispersible tablet.
Example one
Micronizing 20g of Panax notoginsenosides to average particle diameter of 20 nm, adding 2000ml of water and 100g of calcium hydrogen phosphate, homogenizing in homogenizer, adding 1mol/L hydrochloric acid to maintain pH6, and homogenizing until no precipitate exists; introducing the liquid phase into a stirring dryer, adding a sodium carbonate solution into the liquid phase to adjust the pH value to 7, simultaneously stirring, precipitating a precipitate, heating the stirring dryer to 65 ℃, stirring and drying until the water content is 10% to obtain a dry material, taking out the dry material, micronizing to an average particle size of 40 nanometers, adding 27.5g of carboxymethyl starch into the micronized dry material, uniformly mixing, adding 20g of 95% ethanol into the mixture to prepare a soft material, sieving the soft material with a 24-mesh sieve to granulate, preparing wet granules, drying in an environment of 80 ℃, sieving with the 24-mesh sieve to granulate, adding 20g of crosslinked polyvinylpyrrolidone, 2g of magnesium stearate and 0.6g of superfine silica gel powder, uniformly mixing, and tabletting to obtain the Xuesaitong dispersible tablet.
Dissolution testing: detecting notoginsenoside R as main effective component of three notoginsen triterpenes in water with pH of 5.5 and 37 deg.C by using drug dissolution instrument and high performance liquid chromatography1Ginsenoside Rg1Ginsenoside Rb1The dissolution rates were 90 seconds and 120 seconds, respectively, and ten tests were performed at each time point to obtain an average value, and the results are shown in table 1.
Conventional disintegration test: using a disintegration time tester, whether disintegration was completed within 3 minutes and whether the disintegration could pass through a No. 2 sieve was measured in water at 20 ℃ +1 ℃, and the results were averaged for three tests, as shown in Table 2.
Acid environment disintegration test: the disintegration time was measured in 37 degrees water at pH5.5 using a disintegration time tester, and the mean value of three tests was taken as the result of whether the product could pass through No. 2 sieve after complete disintegration, see Table 2.
The liquid with pH of 5.5 and 37 degrees is used for simulating the acidic environment of the human stomach.
Example two
Micronizing 20g of Panax notoginsenosides to average particle diameter of 20 nm, adding 2000ml of water and 100g of calcium hydrogen phosphate, homogenizing in homogenizer, adding 1mol/L hydrochloric acid to maintain pH6, and homogenizing until no precipitate exists; introducing the liquid phase into a stirring dryer, adding a sodium carbonate solution into the liquid phase to adjust the pH value to 7, simultaneously stirring, precipitating a precipitate, heating the stirring dryer to 65 ℃, stirring and drying until the water content is 10% to obtain a dry material, taking out the dry material, micronizing to an average particle size of 60 nanometers, adding 27.5g of carboxymethyl starch into the micronized dry material, uniformly mixing, adding 20g of 95% ethanol into the mixture to prepare a soft material, sieving the soft material with a 24-mesh sieve to granulate, preparing wet granules, drying in an environment of 80 ℃, sieving with the 24-mesh sieve to granulate, adding 20g of crosslinked polyvinylpyrrolidone, 2g of magnesium stearate and 0.6g of superfine silica gel powder, uniformly mixing, and tabletting to obtain the Xuesaitong dispersible tablet.
The disintegration and dissolution test methods are the same as in example one, and the dissolution test results are shown in table 1 and the disintegration test results are shown in table 2.
EXAMPLE III
Micronizing 20g of Panax notoginsenosides to average particle size of 30 nm, adding 2000ml of water and 100g of calcium hydrogen phosphate, homogenizing in homogenizer, adding 1mol/L hydrochloric acid to maintain pH6, and homogenizing until no precipitate exists; introducing the liquid phase into a stirring dryer, adding a sodium carbonate solution into the liquid phase to adjust the pH value to 7, simultaneously stirring, precipitating a precipitate, heating the stirring dryer to 65 ℃, stirring and drying until the water content is 10% to obtain a dry material, taking out the dry material, micronizing to an average particle size of 40 nanometers, adding 27.5g of carboxymethyl starch into the micronized dry material, uniformly mixing, adding 20g of 95% ethanol into the mixture to prepare a soft material, sieving the soft material with a 24-mesh sieve to granulate, preparing wet granules, drying in an environment of 80 ℃, sieving with the 24-mesh sieve to granulate, adding 20g of crosslinked polyvinylpyrrolidone, 2g of magnesium stearate and 0.6g of superfine silica gel powder, uniformly mixing, and tabletting to obtain the Xuesaitong dispersible tablet.
The disintegration and dissolution test methods are the same as in example one, the dissolution test results are shown in Table 1, and the disintegration test results are shown in Table 2
Comparative example 1
In this example, the average particle size of the micronized total saponins of panax notoginseng is modified to 10 nm, compared with the first example, and the rest is the same as the first example.
The disintegration and dissolution test methods are the same as in example one, the dissolution test results are shown in Table 1, and the disintegration test results are shown in Table 2
Comparative example 2
This example was the same as the first example except that only the dry micronized mean particle size was modified to 30 nm.
The disintegration and dissolution test methods are the same as in example one, and the dissolution test results are shown in table 1 and the disintegration test results are shown in table 2.
Comparative example 3
Taking the dispersible tablet prepared in the first embodiment provided by the invention patent in China with the publication number of CN1164264C to perform dissolution test and disintegration test, the disintegration and dissolution test method is the same as that in the first embodiment, the dissolution test result is shown in table 1, and the disintegration test result is shown in table 2.
Comparative example 4
Taking the dispersible tablet prepared by the method of the third embodiment provided in the invention patent of China with the publication number of CN1323667C to perform dissolution test and disintegration test, the disintegration and dissolution test method is the same as the first embodiment, the dissolution test result is shown in table 1, and the disintegration test result is shown in table 2.
Comparative example 5
Taking the dispersible tablet prepared in the first embodiment provided by the invention patent in China with the publication number of CN105055476B to perform dissolution test and disintegration test, the disintegration and dissolution test method is the same as that in the first embodiment, the dissolution test result is shown in table 1, and the disintegration test result is shown in table 2.
Comparative example 6
Micronizing 20g of panax notoginseng saponins to an average particle size of 20 nanometers, adding 100g of calcium hydrophosphate and 27.5g of carboxymethyl starch, uniformly mixing, adding 20g of 95% ethanol into the mixture to prepare a soft material, sieving the soft material with a 24-mesh sieve for granulation, preparing wet granules, drying the wet granules in an environment of 80 ℃, grading the granules with the 24-mesh sieve, adding 20g of crosslinked polyvinylpyrrolidone, 2g of magnesium stearate and 0.6g of superfine silica gel powder, uniformly mixing, and tabletting to obtain the panax notoginseng saponins.
Table 1: dissolution test results
As can be seen from Table 1:
1. the tablet obtained in the embodiment 1 has high dissolution speed and optimal dissolution rate, and the embodiments 1 to 3 can achieve good dissolution speed and dissolution rate;
2. example 1 compared with comparative example 1 and comparative example 2, it can be seen that when the micronized particle size of the raw material of panax notoginseng saponins is too small, or the micronized particle size of the dry material is too small, the dissolution rate is reduced, that is, particle aggregation occurs, and the minimum value of the micronized particle size is tested by comparison, that is, the preparation method and conditions have the highest bioavailability.
3. Example 1 compared with comparative examples 3 to 5, it can be found that the Xuesaitong dispersible tablet provided by the invention can be rapidly dissolved in a short time and achieve a good dissolution rate compared with the Xuesaitong dispersible tablet in the prior art.
4. Compared with the comparative example 6, the embodiment 1 can find that in the comparative example 6, the raw material medicine is also adopted, the micronized particle size is 20 nanometers, only calcium hydrogen phosphate is used as a filler, the subsequent dry material is not subjected to micronization, the disintegration speed and the dissolution rate are not ideal, and the situation that when the raw material is micronized to the particle size of 20 nanometers, particle aggregation occurs in the dissolution process, so that the dissolution rate is insufficient is considered.
Table 2: results of disintegration test
As can be seen from Table 2: examples 1-3 and comparative examples 1-5 all can reach the requirements of the Chinese pharmacopoeia on the dispersible tablets, but under the condition of simulating the acidic environment of the stomach, the dispersible tablets provided by the invention can disintegrate faster than the prior art, and can pass through a No. 2 sieve after disintegration, namely the disintegration effect meets the requirements.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (7)
1. The Xuesaitong dispersible tablet is characterized by comprising panax notoginseng saponins, calcium hydrophosphate, a filler, a disintegrant, a glidant, a lubricant and an adhesive, wherein the Xuesaitong dispersible tablet disintegrates within 60 seconds in a liquid environment with the pH of less than 5.5 and 36-38 ℃, and the 120-second dissolution rate is more than 99%.
2. The Xuesaitong dispersible tablet according to claim 1,
the filler is microcrystalline cellulose;
the disintegrating agent is carboxymethyl starch and cross-linked polyvinylpyrrolidone;
the glidant is magnesium stearate;
the lubricant is micro silica gel powder;
the binder was 95% ethanol.
3. The Xuesaitong dispersible tablet according to claim 2, wherein the ingredients comprise 20 parts by weight of panax notoginseng saponins, 90-110 parts by weight of calcium hydrogen phosphate, 60-80 parts by weight of microcrystalline cellulose, 20-30 parts by weight of carboxymethyl starch, 10-30 parts by weight of cross-linked polyvinylpyrrolidone, 1-10 parts by weight of magnesium stearate, 1-5 parts by weight of aerosil and 20-30 parts by weight of 95% ethanol.
4. A method for preparing a Xuesaitong dispersible tablet according to any one of claims 1 to 3, comprising the steps of:
s1 micronizing the Panax notoginsenosides;
s2 adding micronized total saponins of Notoginseng radix into water, adding calcium hydrogen phosphate, homogenizing in a homogenizer, and adding hydrochloric acid to maintain pH6-6.5 during homogenizing until no precipitate exists;
s3 adding sodium carbonate solution into the liquid phase of S2 while stirring until the pH is 7, and simultaneously separating out a precipitate;
s4, stirring and drying the precipitate and the liquid phase in the S3 at the temperature of not higher than 70 ℃ until the water content is less than 10 percent to obtain a dry material;
s5, micronizing the dry material, adding carboxymethyl starch, and uniformly mixing;
s6, adding 95% ethanol to prepare soft materials, granulating, and drying the wet granules at a temperature higher than 75 ℃;
s7 granulating, adding magnesium stearate, silica gel micropowder, and crosslinked polyvinylpyrrolidone, mixing, and tabletting to obtain XUESAITONG dispersible tablet.
5. The method for preparing Xuesaitong dispersible tablet according to claim 4, wherein the dosage of each component is as follows: 20 parts of panax notoginseng saponins, 90-110 parts of calcium hydrophosphate, 60-80 parts of microcrystalline cellulose, 20-30 parts of carboxymethyl starch, 10-30 parts of cross-linked polyvinylpyrrolidone, 1-10 parts of magnesium stearate, 1-5 parts of superfine silica gel powder and 20-30 parts of 95% ethanol.
6. The method for preparing Xuesaitong dispersible tablet according to claim 5, wherein the micronized particle size in step S1 is 20-30 nm.
7. The method for preparing Xuesaitong dispersible tablet according to claim 6, wherein the micronized particle size in step S5 is 40-60 nm.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110084700.3A CN112618590A (en) | 2021-01-22 | 2021-01-22 | Xuesaitong dispersible tablet and preparation method thereof |
| PCT/CN2021/118216 WO2022156240A1 (en) | 2021-01-22 | 2021-09-14 | Xuesaitong dispersible tablet and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110084700.3A CN112618590A (en) | 2021-01-22 | 2021-01-22 | Xuesaitong dispersible tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112618590A true CN112618590A (en) | 2021-04-09 |
Family
ID=75295534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110084700.3A Pending CN112618590A (en) | 2021-01-22 | 2021-01-22 | Xuesaitong dispersible tablet and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112618590A (en) |
| WO (1) | WO2022156240A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022156240A1 (en) * | 2021-01-22 | 2022-07-28 | 海南海力制药有限公司 | Xuesaitong dispersible tablet and preparation method therefor |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116115665A (en) * | 2023-01-16 | 2023-05-16 | 江中药业股份有限公司 | Chinese angelica blood replenishing tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1762400A (en) * | 2004-09-24 | 2006-04-26 | 贵阳云岩西创药物科技开发有限公司 | 'Xuesaitong' formulation and its preparation method |
| CN1323667C (en) * | 2004-08-04 | 2007-07-04 | 云南白药集团股份有限公司 | Notoginseng dispersible tablet and its preparing process |
| CN105055476B (en) * | 2015-08-24 | 2019-01-15 | 江苏红瑞制药有限公司 | A kind of Xuesaitong dispersible tablet and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618590A (en) * | 2021-01-22 | 2021-04-09 | 海南海力制药有限公司 | Xuesaitong dispersible tablet and preparation method thereof |
-
2021
- 2021-01-22 CN CN202110084700.3A patent/CN112618590A/en active Pending
- 2021-09-14 WO PCT/CN2021/118216 patent/WO2022156240A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323667C (en) * | 2004-08-04 | 2007-07-04 | 云南白药集团股份有限公司 | Notoginseng dispersible tablet and its preparing process |
| CN1762400A (en) * | 2004-09-24 | 2006-04-26 | 贵阳云岩西创药物科技开发有限公司 | 'Xuesaitong' formulation and its preparation method |
| CN105055476B (en) * | 2015-08-24 | 2019-01-15 | 江苏红瑞制药有限公司 | A kind of Xuesaitong dispersible tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘强 等主编: "《中药新产品开发》", 31 March 2013, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022156240A1 (en) * | 2021-01-22 | 2022-07-28 | 海南海力制药有限公司 | Xuesaitong dispersible tablet and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022156240A1 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112618590A (en) | Xuesaitong dispersible tablet and preparation method thereof | |
| CN106456626A (en) | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same | |
| CN104546747A (en) | Pharmaceutical composition containing safinamide mesylate and preparation method of pharmaceutical composition | |
| JP2016539955A (en) | Drug composition, method for producing the same, and use | |
| CN105078915A (en) | Rivaroxaban tablets and preparation method for same | |
| WO2015081703A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
| CN107913256A (en) | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof | |
| CN109793715B (en) | Apixaban oral solid preparation and preparation method thereof | |
| WO2021254409A1 (en) | Pharmaceutical composition of complex and preparation method therefor | |
| CN103393612B (en) | Preparation method for enalapril maleate orally disintegrating tablets | |
| CN101269014B (en) | Orally disintegrating tablet of risperidone and preparation method thereof | |
| KR20130106456A (en) | Composition for controlled release of drug | |
| CA2782498C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
| CN115177595A (en) | Oxagolide sodium tablet and preparation method thereof | |
| CN112691132A (en) | Xuesaitong dispersible tablet and preparation method thereof | |
| CN103467484A (en) | Compound and medicine composition containing micronized prasugrel and salts of prasugrel | |
| CN108721238A (en) | A kind of lithium carbonate sustained release tablets | |
| CN108078933A (en) | A kind of tolvaptan dispersible tablet and preparation method thereof | |
| CN114191404A (en) | Totiravi tablet and preparation method thereof | |
| CN112516097B (en) | Levamlodipine besylate composition | |
| CN100355430C (en) | Tibetan medicine for treating eye diseases, and its preparing method | |
| CN102485221B (en) | Sublingual pharmaceutical composition containing ibutilide and preparation method thereof | |
| CN100544706C (en) | The preparation technology of vitamin U belladonna aluminum dispersible tablet | |
| CN100402060C (en) | Heart beneficial keton dispersion tablet and its preparation method | |
| CN109498584A (en) | A kind of dispersible tablet and its novel processing step containing Letrozole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210409 |
|
| RJ01 | Rejection of invention patent application after publication |